Burning Rock discovered novel OverC™ Multi-Cancer Detection Blood Test (MCDBT) for multiple cancer types such as esophageal, liver, lung, ovarian, and pancreatic cancers.
OverC™ MCDBT detects early multiple cancer types among adults aged 50-75 years old, at average risk for cancer.
Compared to other traditional cancer screening methods, liquid biopsy has shown the potential to increase detection efficiency, enabling early diagnosis and treatment, improving patient survival and quality of life, reducing the social burden of the disease.
In a case control study, the test has demonstrated 69.1% of sensitivity and 98.9% of specificity. "Detected" test results for one or two of the highest predicted tissue-of-origin cancer-related signals indicating the presence of cancer and should be followed up with diagnostic tests recommended by qualified health care professionals according to professional guidelines. "Undetectable" test results does not rule out the presence of cancer, and individuals should continue the recommended treatment with screening tests as directed.
US Food and Drug Administration (FDA) grants Breakthrough Device Designation for the OverC™ Multi-Cancer Detection Blood Test.
